enGene (NASDAQ:ENGN) Receives “Market Outperform” Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of enGene (NASDAQ:ENGN) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $18.00 target price on the stock.

A number of other research analysts also recently commented on ENGN. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of enGene in a report on Tuesday, September 24th. Raymond James initiated coverage on enGene in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. Morgan Stanley reiterated an “overweight” rating and set a $40.00 target price on shares of enGene in a research note on Wednesday, September 11th. Finally, HC Wainwright assumed coverage on enGene in a research note on Monday. They issued a “buy” rating and a $25.00 price target on the stock. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $29.78.

enGene Trading Up 2.2 %

Shares of NASDAQ:ENGN opened at $5.96 on Monday. The stock has a market capitalization of $263.53 million, a PE ratio of -10.28 and a beta of -0.78. The company’s 50-day moving average price is $8.13 and its two-hundred day moving average price is $7.80. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. enGene has a one year low of $4.42 and a one year high of $18.40.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, equities analysts forecast that enGene will post -1.52 EPS for the current fiscal year.

Insider Activity at enGene

In other enGene news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the business’s stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $5.70 per share, with a total value of $57,000.00. Following the acquisition, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $57,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion bought 41,639 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average cost of $5.97 per share, for a total transaction of $248,584.83. Following the completion of the acquisition, the insider now directly owns 2,059,459 shares of the company’s stock, valued at approximately $12,294,970.23. This trade represents a 2.06 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 420,965 shares of company stock worth $2,651,103 in the last ninety days. 13.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On enGene

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC acquired a new stake in shares of enGene during the 3rd quarter worth $37,000. Point72 Asset Management L.P. lifted its position in enGene by 1,410.3% during the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares during the period. SR One Capital Management LP acquired a new stake in enGene during the second quarter worth about $4,715,000. Franklin Resources Inc. increased its holdings in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after buying an additional 389,918 shares during the period. Finally, Logos Global Management LP increased its holdings in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the period. 64.16% of the stock is owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.